ERBB2 and Obesity: With respect to HER2-overexpressing tumors, researchers in a phase III clinical trial (N9831) that incorporated trastuzumab adjuvant therapy for HER2+ breast cancer observed poorer breast cancer-specific survival in the setting of obesity [20].